Current Hypertension Reviews最新文献

{"title":"Treatment Adherence and Associated Factors Among Hypertensive Patients in Can Tho City, Vietnam: a Cross-sectional Study.","authors":"Ba Nam Nguyen, Cuong Le, Huong Duong, Khue La, Tuan Nguyen, Quang La","doi":"10.2174/0115734021501463261007104548","DOIUrl":"https://doi.org/10.2174/0115734021501463261007104548","url":null,"abstract":"<p><strong>Introduction: </strong>Hypertension control depends strongly on treatment adherence, yet adherence remains suboptimal in many low- and middle-income countries. Addressing suboptimal hypertension treatment adherence is a public health priority in developing countries like Vietnam. This study aimed to determine the level of treatment adherence and identify factors associated with nonadherence to hypertension treatment among patients in Can Tho City, Vietnam.</p><p><strong>Methods: </strong>A cross-sectional study was conducted among 434 hypertensive patients managed at commune health stations in Can Tho City, Vietnam, in 2022. Treatment adherence was assessed across six domains, including medication adherence (MMAS-8), diet, smoking cessation, alcohol restraint, physical activity, and follow-up monitoring. Multivariable logistic regression was used to identify factors associated with non-adherence.</p><p><strong>Results: </strong>Overall treatment adherence was 45.6%. Medication adherence was 59.0%, whereas adherence to follow-up monitoring was 48.8%. Female patients demonstrated significantly higher overall treatment adherence than males (55.5% vs. 30.4%, p < 0.001). In multivariable analyses, male sex, lack of health insurance, poor patient-doctor relationship, and not actively seeking hypertensionrelated information were independently associated with non-adherence. Sex-stratified analyses further identified differences in factors associated with non-adherence between men and women. In addition, patients with treatment adherence had significantly lower systolic and diastolic blood pressure than non-adherent patients.</p><p><strong>Discussion: </strong>Treatment adherence among hypertensive patients remained suboptimal. Poor patientdoctor relationship was consistently associated with non-adherence, while factors associated with non-adherence differed between men and women. Better treatment adherence was also associated with lower blood pressure.</p><p><strong>Conclusion: </strong>Treatment adherence among hypertensive patients in Can Tho City remained suboptimal. Interventions focusing on strengthening patient-doctor relationships, improving patient education and engagement, and reducing financial barriers may improve long-term treatment adherence and hypertension management.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":""},"PeriodicalIF":1.1,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149185126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preface.","authors":"Guido Grassi","doi":"10.2174/011573402112168260917095157","DOIUrl":"https://doi.org/10.2174/011573402112168260917095157","url":null,"abstract":"","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":""},"PeriodicalIF":1.1,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149167994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic Inertia in the Management of Hypertension by Moroccan General Practitioners.","authors":"Badia Al Outmani, Asmae Yeznasni, Naima Abda, Zakaria Bazid, Nabila Ismaili, Noha El Ouafi","doi":"10.2174/0115734021447979260925070423","DOIUrl":"https://doi.org/10.2174/0115734021447979260925070423","url":null,"abstract":"<p><strong>Background: </strong>Therapeutic inertia has been identified as a major factor in poor blood pressure control. This study aimed to investigate factors associated with therapeutic inertia in hypertension management among Moroccan General Practitioners (GPs).</p><p><strong>Methods: </strong>A descriptive and analytical cross-sectional study was conducted from October 2021 to January 2022, involving Moroccan general practitioners using an anonymous questionnaire developed specifically for this study, covering numerous areas: their socio-demographic characteristics, assessment of hypertension knowledge, reasons not to intensify therapy, and clinical scenarios. A univariate analysis was performed using the Chi-square test to compare percentages. A multivariable logistic regression analysis was also applied to study variables possibly associated with therapeutic inertia.</p><p><strong>Results: </strong>A total of 130 physicians participated in this study. Most of the practitioners were female (62.3%). The median age was 32 years (IQR, 26-50). The percentage of physicians who had practiced for 5 years or less was 51.5%, compared with 48.5% who had practiced for more than 5 years. The median number of patients seen per day was estimated at 30 patients with an interquartile range of [15, 50]. The median consultation duration was 10 minutes (IQR, 5-15). Using the study-defined cutoff of ≥2, 78.5% of physicians met the criterion for therapeutic inertia (95% CI, 70.4%-85.2%). Furthermore, the two main reasons for therapeutic abstention reported by physicians were: the importance of improving patient compliance, lifestyle, and dietary measures before intensifying treatment (81.5%), in addition to the perception that office blood pressure does not reflect the patient's \"true\" blood pressure (BP) and therefore does not support immediate treatment intensification without further ambulatory monitoring (43.8%).</p><p><strong>Discussion: </strong>This study found a high prevalence of therapeutic inertia in primary care. The study's results found that the advanced age of the hypertensive patient was inversely related to clinical inertia. Multivariable regression showed that when the patient is diabetic, the general practitioners tend to be 4 times more 'therapeutically inert' [OR 4.42 (95% CI 1.2-7.23)]. A patient's history of ischemic stroke was also positively associated with Therapeutic Inertia (TI) [OR 1.53 (95% CI 1.23-4.23)].</p><p><strong>Conclusion: </strong>Therapeutic inertia was common among participating Moroccan general practitioners and varied across clinical contexts. According to our study, the history of diabetes or stroke was positively associated with inertia. Given the exploratory nature of the study and its sampling limitations, these findings require confirmation in larger and more representative studies.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":""},"PeriodicalIF":1.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149168969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Efficacy of Polypill with a Focus on Blood Pressure Control: A Systematic Review and Meta-analysis.","authors":"Andrey Garanin, Olesya Aydumova, Anatoly Rubanenko","doi":"10.2174/0115734021483573260921051313","DOIUrl":"https://doi.org/10.2174/0115734021483573260921051313","url":null,"abstract":"<p><strong>Introduction: </strong>The effectiveness of controlling blood pressure when prescribing a fixed combination (\"polypill\") compared to monocomponent drugs has not been fully determined. According to the studies conducted, some demonstrate statistically significant differences in mean blood pressure levels when taking a \"polypill\" compared to monocomponent drugs, while others do not reveal this effect. The aim was to evaluate the efficacy of \"polypill\" in lowering blood pressure in patients with Cardiovascular (CV) diseases compared to monocomponent drugs.</p><p><strong>Methods: </strong>The search was conducted according to PRISMA guidelines in PubMed, Google Scholar, and ClinicalTrials databases. Finally, 10 studies were selected. The dynamics of the mean systolic and diastolic pressure in patients taking \"polypill\" was evaluated in comparison to monocomponent drugs.</p><p><strong>Results: </strong>During the identification stage, 568 publications were found. At the screening phase, 321 papers, such as books, reviews, systematic reviews, meta-analyses, etc were excluded. 168 papers were assessed for eligibility. After the eligibility assessment, 158 papers were excluded for deviations from the study design (e.g., no control group, no direct comparison between \"polypill\" and monocomponent drug therapy, data presented as median and interquartile range, placebo as the control group, etc.). In the final analysis, we included 10 publications that evaluated the effect of a fixed combination of medications (\"polypill\") compared with monocomponent therapy on blood pressure. During further sub-analyses, 1 study was excluded. The meta-analysis of the clinical efficacy of \"polypill\" control of blood pressure was conducted in comparison with standard therapy and comprised 9 studies, involving patients with previous myocardial infarction, acute cerebrovascular accident, high CV risk, hypertension and dyslipidemia. In total, all of the studies enrolled 6264 people, of whom 3147 patients received \"polypill\", and 3117 patients - monocomponent drugs. The meta-analysis demonstrated that fixed-dose combination therapy yielded a statistically significant difference compared to standard therapy with respect to its impact on systolic (standardized mean difference: -0.128; (-0.177; -0.08); p < 0.01) and diastolic (standardized mean difference: -0.171; (-0.233; -0.11); p < 0.01) blood pressure.</p><p><strong>Discussion: </strong>The findings of the conducted meta-analysis support the evidence of beneficial switching to \"polypill\" therapy in patients with hypertension, especially in cases requiring a multi-drug regimen.</p><p><strong>Conclusion: </strong>\"Polypill\" therapy in patients with CV diseases, hypertension, dyslipidemia, and high CV risk is associated with more effective blood pressure control compared to monocomponent drugs.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":""},"PeriodicalIF":1.1,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149138708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Review Highlighting Emerging Frontiers in Hypertension Management: Integrating Novel Therapeutics and Holistic Approaches.","authors":"Nishant Gaurav, Sumita Singh, Vishal Kumar Biswkarma","doi":"10.2174/0115734021472294260830065452","DOIUrl":"https://doi.org/10.2174/0115734021472294260830065452","url":null,"abstract":"<p><p>Despite the availability of various antihypertensive medications, hypertension (HTN) remains a major global cause of heart disease, stroke, renal damage, and early mortality. This narrative summary describes current advances and new directions in HTN treatment beyond prescription drugs. We used PubMed, Scopus, Web of Science, and Google Scholar to conduct a comprehensive literature search for papers published between 2000 and 2026. A careful evaluation and combination of pertinent clinical trials, systematic reviews, meta-analyses, international recommendations, and important research about innovative blood pressure therapies, device-based interventions, digital health tools, personalized medicine, and advances in public health were conducted. In addition to highlighting novel pharmacological treatments such as aldosterone synthase inhibitors, RNA interference- based medicines, and endothelin pathway regulators, this study examines the shortcomings of traditional blood pressure drugs. Device-based methods, such as renal denervation and baroreceptor activation therapy, along with digital therapeutics, remote healthcare, wearable monitoring equipment, and AI-supported clinical decision-making tools, are also being explored. Additionally, personalized medicine strategies involving genetics, metabolomics, biomarker-directed treatment, lifestyle improvements, and public health programs, including WHO HEARTS and India IHCI, are discussed. While many emerging strategies show promising results in reducing blood pressure, significant constraints persist regarding evidence of long-term cardiovascular outcomes, cost, availability, and applicability across varied populations. Future HTN management will likely require integrated, patient-focused, technology-driven, and precision-guided approaches to achieve lasting and equitable cardiovascular risk reduction worldwide.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":""},"PeriodicalIF":1.1,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148971713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preeclampsia-associated Biomarkers and their Potential Relevance to Stillbirth Risk: A Tutorial Review.","authors":"Alycia Devasagayam, Stalin Selvaraj","doi":"10.2174/0115734021496393260828062926","DOIUrl":"https://doi.org/10.2174/0115734021496393260828062926","url":null,"abstract":"<p><p>Stillbirth remains a major global public health challenge, accounting for nearly two million deaths annually despite significant advances in antenatal and obstetric care. Reliable biomarkers for its early prediction are still lacking, highlighting the need to identify novel diagnostic strategies. Since preeclampsia and stillbirth share several underlying pathophysiological mechanisms, including placental insufficiency, impaired trophoblast invasion, endothelial dysfunction, angiogenic imbalance, oxidative stress, and systemic inflammation, biomarkers established for preeclampsia may also hold promise for stillbirth risk assessment. This tutorial review summarizes current evidence on protein- and metabolome-based biomarkers used for the early diagnosis of preeclampsia and evaluates their potential applicability for predicting stillbirth. A comprehensive literature search of Scopus, PubMed, and ScienceDirect was conducted for studies published between 2010 and 2024. Conventional fetal monitoring techniques such as ultrasonography, magnetic resonance imaging (MRI), and cardiotocography (CTG) remain valuable for assessing fetal well-being but offer limited predictive accuracy for stillbirth. Several biomarkers, including angiogenic factors (sFlt-1, PLGF, sEng), placental proteins (PP13, PAPP-A), cardiovascular markers (BNP, NT-proBNP), renal biomarkers (cystatin C), metabolic markers (uric acid), and emerging candidates such as growth differentiation factor- 15 (GDF-15), have demonstrated diagnostic value in preeclampsia. However, their clinical utility for stillbirth prediction remains insufficiently validated. Prospective studies involving dedicated stillbirth cohorts are essential to establish their predictive performance and facilitate translation into routine clinical practice.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":""},"PeriodicalIF":1.1,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148946042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High Heart Rate: A Possible Treatment Target in Hypertensive Patients with Tachycardia.","authors":"Paolo Palatini, Francesca Saladini, Guido Grassi","doi":"10.2174/0115734021511536260827063425","DOIUrl":"https://doi.org/10.2174/0115734021511536260827063425","url":null,"abstract":"","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":""},"PeriodicalIF":1.1,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148945998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Value of Non-dipping Blood Pressure Patterns in Normotensive and Hypertensive Patients With Chronic Kidney Disease: A Systematic Review.","authors":"Rizqa Adinda Syakira, Mutia Ammara Widodo, Rizky Andhika","doi":"10.2174/0115734021499546260818115459","DOIUrl":"https://doi.org/10.2174/0115734021499546260818115459","url":null,"abstract":"<p><strong>Background: </strong>Non-dipping Blood Pressure (BP) patterns, which are highly prevalent among patients with Chronic Kidney Disease (CKD), are independent predictors of cardiovascular risk regardless of average BP levels. However, whether non-dipping independently predicts renal progression beyond overall BP burden remains uncertain.</p><p><strong>Methods: </strong>This review followed PRISMA guidelines across PubMed, Scopus, and Cochrane databases. Cohort studies evaluating non-dipping patterns using ambulatory blood pressure monitoring (ABPM) and renal outcomes in CKD were included.</p><p><strong>Result: </strong>Six cohort studies involving 4,303 patients were included. Across studies, renal outcomes appeared more strongly associated with overall BP control than with dipping status alone. Studies comparing normotensive and hypertensive groups showed that hypertensive dippers and non-dippers experienced faster renal decline and higher ESRD rates. Exploratory pooled data demonstrated that non-dipping with uncontrolled hypertension increased ESRD risk (HR 1.42; 95% CI 1.19-1.69; p < 0.0001). Among controlled patients, non-dippers with on-target BP had lower renal risk than dippers above target.</p><p><strong>Discussion: </strong>The findings suggest that the prognostic significance of non-dipping may depend on overall blood pressure control rather than dipping status alone. Among patients with uncontrolled hypertension, non-dippers appeared to be at greater risk of renal progression than dippers.</p><p><strong>Conclusion: </strong>Among patients with uncontrolled hypertension, non-dippers appeared to be at greater risk of renal progression than dippers. These findings suggest that the prognostic impact of nondipping may be influenced by overall blood pressure control and highlight the importance of achieving adequate 24-hour blood pressure control in patients with CKD.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":""},"PeriodicalIF":1.1,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Heart Failure in Early Adulthood: A Systematic Review of Contributory Clinical and Lifestyle Factors.","authors":"Vaishnavi B, Sunil Kumar Kadiri","doi":"10.2174/0115734021469869260821101314","DOIUrl":"https://doi.org/10.2174/0115734021469869260821101314","url":null,"abstract":"<p><strong>Background: </strong>The rising incidence of congestive heart failure in younger adults, traditionally linked to older demographics, necessitates a thorough examination of relevant clinical and lifestyle factors. This study analyzes the factors influencing congestive heart failure in early adulthood, focusing on genetic predispositions, congenital cardiac defects, and acquired risk factors such as hypertension, diabetes, and obesity.</p><p><strong>Methods: </strong>An extensive and comprehensive literature search was undertaken across multiple scholarly databases, including PubMed, Scopus, Web of Science, ScienceDirect, and Google Scholar. The systematic review integrates findings from the selected relevant sources to provide a broad overview of the current state of knowledge in this field, distinguishing it from systematic reviews conducted in accordance with PRISMA guidelines.</p><p><strong>Results: </strong>Recent studies emphasize the interaction between genetic markers and environmental factors that contribute to the acceleration of cardiac dysfunction in younger populations. Prolonged diagnosis and insufficient screening expedite disease advancement, highlighting the essential need for early detection measures.</p><p><strong>Discussion: </strong>Various management approaches, including pharmacological interventions and lifestyle modifications, are examined with a focus on long-term outcomes. Preventive strategies, such as public health initiatives and patient education, are essential for reducing incidence rates.</p><p><strong>Conclusion: </strong>This review highlights the pressing need for targeted research and healthcare reforms to address the rising incidence of heart failure in early adulthood. Identifying key risk factors and promoting preventive strategies enable clinicians and policymakers to improve early intervention and patient outcomes.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":""},"PeriodicalIF":1.1,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging Pharmacological Therapies for Hypertension.","authors":"Pritesh Mahajan, Ashish Pagar, Kajal Baviskar, Ramanlal Kachave","doi":"10.2174/0115734021449960260727113527","DOIUrl":"https://doi.org/10.2174/0115734021449960260727113527","url":null,"abstract":"<p><p>This review provides a general overview of the physiological effects and pharmacokinetic properties that affect the absorption, distribution, metabolism, and elimination of recently developed antihypertensive drugs, such as fimasartan, azilsartan, zilebesiran, aprocitentan, and esaxerenone. It provides an opportunity to understand the pharmacologic properties of drugs like esaxerenone, a non-steroidal selective mineralocorticoid receptor antagonist; aprocitentan, a dual endothelin receptor antagonist; and zilebesiran, a small interfering RNA (siRNA) therapeutic that inhibits hepatic angiotensinogen synthesis. Mechanistic differences among these agents are also highlighted; for instance, fimasartan and azilsartan inhibit the angiotensin II receptor, whereas other medications alter mineralocorticoid activity or endothelial pathways. The review further discusses the clinical implications of these mechanisms in hypertension management and supports informed therapeutic decisionmaking by providing a detailed understanding of the pharmacological and mechanistic profiles of these emerging antihypertensive therapies.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":""},"PeriodicalIF":1.1,"publicationDate":"2026-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148809135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}